Rencken R K, Bornman M S, Reif S, Olivier I
Department of Urology, Medical University of Southern Africa.
Br J Urol. 1990 Apr;65(4):382-4. doi: 10.1111/j.1464-410x.1990.tb14761.x.
We present a prospective single-blind trial of sclerotherapy for hydroceles with tetradecyl sulphate and rolitetracycline as sclerosants. Twenty-seven hydroceles were treated with tetradecyl sulphate and 28 with rolitetracycline. The median follow-up was 13 months. There were no statistically significant differences between the 2 drugs in respect of cure rate and complications. The overall cure rate for both drugs was 96%. Complications were rare and common to both drugs. Tetradecyl sulphate and rolitetracycline were found to be equally effective as sclerosants.
我们开展了一项前瞻性单盲试验，以十四烷基硫酸盐和罗利环素作为硬化剂治疗鞘膜积液。27例鞘膜积液患者接受了十四烷基硫酸盐治疗，28例接受了罗利环素治疗。中位随访时间为13个月。两种药物在治愈率和并发症方面无统计学显著差异。两种药物的总体治愈率均为96%。并发症罕见且两种药物都有。结果发现，十四烷基硫酸盐和罗利环素作为硬化剂同样有效。
